A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

By G. D'andrea, Rosa Lucia D’Ambrosio, P. Di Perna, M. Chetta, R. Santacroce, V. Brancaccio, E. Grandone, M. Margaglione. Blood, 2005

724 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/585e3c6b5456ce5ad13461dbcbdd4d1064cabb4a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. F. Takeuchi
2. B. Horne
3. J. Muhlestein
4. R. McGinnis
5. N. Eriksson
6. Jessica L. Clarke
7. P. Deloukas
8. J. Lindh

Citations in the corpus

• Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study (2006, background): “The wild type (CC) genotype was found to be associated with almost twice the warfarin dose requirement as the TT genotype [15].”
• A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose (2009, background): “We and others have shown that the warfarin drug target VKORC1 (vitamin K epoxide reductase complex, subunit 1) contains common polymorphisms that account for a major portion (,30%) of the variance in required warfarin dose [5,6], and we have recently evaluated ,1500 Swedish patients of the Warfarin ”